Navigation Links
Hospira MedNet™ Portal Safety Software Benchmarking System Debuts at HIMSS
Date:2/23/2011

ORLANDO, Fla., Feb. 23, 2011 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), a leading provider of clinical information and medication delivery technologies, today announced the unveiling of the Hospira MedNet™ Portal at the Healthcare Information and Management Systems Society (HIMSS) Annual Conference and Exhibition in Orlando. This web-based application will provide healthcare institutions with advanced medication error reporting and patient safety benchmarking capabilities. It will be available as an add-on feature to the award-winning Hospira MedNet safety software.

Hospira MedNet Portal, on demonstration at HIMSS booth 6449, improves a hospital's ability to monitor, benchmark and evaluate intravenous (I.V.) drug administration practices. With this new technology, healthcare institutions will have access to side-by-side, blinded comparisons of their own safety software drug libraries and infusion performance data with the same information from other institutions. Users can look at data by hospital size, institution type or specific clinical care areas to help them develop and refine their drug library. The software system also allows clinicians and hospital staff to view internal and external peer benchmarking reports to drive improved I.V. medication safety and to help enhance clinical and operational outcomes. Hospira MedNet Portal supports continuous quality improvement efforts by helping users analyze key aspects of their drug administration process against best practices and by providing a more complete picture of clinical performance indicators.

"Our hospital customers are telling us that they're not just buying infusion pumps, they're also investing in the safety data that comes from the infusion devices," said Richard Nevin, vice president, Medication Management Systems, U.S., Hospira. "Hospira MedNet Portal will help give every facility a better view of their medication administration and safety performance, allowing them to benchmark against how other institutions are practicing medicine, and driving safety and continuous quality improvement programs."

Hospira MedNet Portal will be available as a value-added feature for healthcare institutions using Hospira MedNet safety software with their Hospira infusion technologies, such as the Plum A+™ with Hospira MedNet safety software, a proven and scaleable infusion pump system; the technologically advanced Symbiq™ infusion system with built-in Hospira MedNet; and the market-leading LifeCare PCA™ pump with Hospira MedNet. Hospira is also the U.S. leader in I.V. clinical integration of infusion pumps with electronic health record systems.

The company is targeting mid-year for making Hospira MedNet Portal available to Hospira MedNet customers.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.

Private Securities Litigation Reform Act of 1995 --

A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the timing of availability of the Hospira MedNet Portal to customers. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, regulatory, legal, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
2. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
3. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
4. Hospira to Present at Credit Suisse 18th Annual Healthcare Conference Nov. 11
5. Hospira Names Daphne E. Jones Chief Information Officer
6. Hospira Reports Third-Quarter 2009 Results
7. Hospira Supports Disaster Relief Efforts in Haiti With Products and Cash Grants
8. Hospira to Present at J.P. Morgan 28th Annual Healthcare Conference Jan. 13, 2010
9. Hospira to Host Conference Call for Fourth-Quarter 2009 Results and 2010 Projections
10. Hospira Acquires TheraDoc, Enhances Medication Safety and Infection Management Offerings
11. Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Calif. , Jan. 19, 2017   Science ... is excited to announce that the first five ... Biology  (RP:CB) have been published in eLife today. ... project represents the first practical evaluation of reproducibility ... in reproducible studies. Unlike other assessments of reproducibility, ...
(Date:1/19/2017)... NEW YORK , January 18, 2017 , , ... rd distribution agreement, following similar agreements ...   , Wound care is $2 5 ...   , E-QURE Corp. (OTCQB: EQUR), a leader in medical devices ... agreement with Tech - Médica Equipos Médicos S.A.S. (TeckMedica) in Colombia ...
(Date:1/19/2017)... , Jan. 18, 2017 The drug ... billion by 2021 from USD 1,179.20 billion in 2016, ... Increasing prevalence of chronic diseases, increasing demand for ... factors driving the growth of this market. Whereas, self-administration ... generic drugs offer significant growth opportunities for players operating ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out ... announced it attended the January ECRM trade show in Hilton Head, SC. , ... was determined to create a line of products that would elevate her fitness regime. ...
(Date:1/20/2017)... ... , ... “Mary Magdalene: Grace is Greater than Sin”: a unique and ... Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of published ... with countless women who had little knowledge of the female characters portrayed in the ...
(Date:1/20/2017)... ... 20, 2017 , ... D R Burton Healthcare Products LLC, ... featured in a study indicating superior performance against competitive products in secretion clearance. ... Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the winter ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Land of More and More”: ... of world hunger, and shares the simple and achievable answer. “The Land of More ... of the Fairview Missionary Church in Angola, Indiana where he works with the children’s ...
(Date:1/19/2017)... ... 19, 2017 , ... Next week after January 20th, the fear for many ... that circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis ... government public servants were suppose to prioritize. Interviews provided below. , Among ...
Breaking Medicine News(10 mins):